TN2010000304A1 - New processes - Google Patents

New processes

Info

Publication number: TN2010000304A1
Authority: TN; Tunisia
Prior art keywords: nep inhibitors; new processes; ester; group; carboxyl group
Prior art date: 2008-01-17

Application number

TN2010000304A

Other languages

English (en)

Inventor

David Hook

Bernhard Riss

Daniel Kaufmann

Matthias Napp

Erhard Bappert

Philippe Polleux

Jonathan Medlock

Antonio Zanotti-Gerosa

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-17

Filing date

2010-06-30

Publication date

2011-11-11

2010-06-30 Application filed by Novartis Ag filed Critical Novartis Ag

2011-11-11 Publication of TN2010000304A1 publication Critical patent/TN2010000304A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2010000304A 2008-01-17 2010-06-30 New processes TN2010000304A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08150353		2008-01-17
PCT/EP2009/050510 WO2009090251A2 (fr)	2008-01-17	2009-01-16	Nouveaux procédés

Publications (1)

Publication Number	Publication Date
TN2010000304A1 true TN2010000304A1 (en)	2011-11-11

Family

ID=40758693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000304A TN2010000304A1 (en)	2008-01-17	2010-06-30	New processes

Country Status (29)

Country	Link
US (4)	US8580974B2 (fr)
EP (1)	EP2245009B1 (fr)
JP (2)	JP5739667B2 (fr)
KR (1)	KR101587668B1 (fr)
CN (2)	CN103483236B (fr)
AR (1)	AR070176A1 (fr)
AU (1)	AU2009204759B2 (fr)
BR (1)	BRPI0906764A2 (fr)
CA (1)	CA2711529C (fr)
CL (1)	CL2009000089A1 (fr)
CO (1)	CO6290677A2 (fr)
EC (1)	ECSP10010405A (fr)
ES (1)	ES2602564T3 (fr)
GT (1)	GT201000211A (fr)
HU (1)	HUE030606T2 (fr)
IL (1)	IL206664A0 (fr)
MA (1)	MA31951B1 (fr)
MX (1)	MX2010007842A (fr)
MY (1)	MY169425A (fr)
NZ (2)	NZ586657A (fr)
PE (1)	PE20091364A1 (fr)
PL (1)	PL2245009T3 (fr)
PT (1)	PT2245009T (fr)
RU (2)	RU2513521C2 (fr)
SG (1)	SG187491A1 (fr)
SI (1)	SI2245009T1 (fr)
TN (1)	TN2010000304A1 (fr)
TW (1)	TWI422370B (fr)
WO (1)	WO2009090251A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20091364A1 (es) *	2008-01-17	2009-10-13	Novartis Ag	Proceso para la preparacion de inhibidores de nep
US8450496B2 (en) *	2009-03-24	2013-05-28	Hoffman-La Roche Inc.	Process for the preparation of propionic acid derivatives
KR20120041702A (ko)	2009-05-28	2012-05-02	노파르티스 아게	네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
CA2763572C (fr)	2009-05-28	2017-10-17	Novartis Ag	Derives aminopropioniques substitues comme inhibiteurs de neprilysine
CN102639486B (zh)	2009-09-23	2014-12-31	浙江九洲药业股份有限公司	生产n-酰基联苯基丙氨酸的方法
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102712585B (zh) *	2010-01-22	2015-06-24	诺华股份有限公司	中性内肽酶抑制剂中间体和其制备方法
CN103080077B (zh) *	2010-08-23	2015-06-10	诺华股份有限公司	用于制造nep抑制剂的中间体的制备工艺
BR112013004164A2 (pt)	2010-08-23	2016-05-10	Novartis Ag	processo para a preparação de intermediários para a produção de inibidores da nep
WO2012025502A1 (fr)	2010-08-23	2012-03-01	Novartis Ag	Nouveau procédé de préparation d'intermédiaires utilisés pour produire des inhibiteurs de l'endopeptidase neutre (epn)
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN105061314A (zh)	2010-12-15	2015-11-18	施万生物制药研发Ip有限责任公司	脑啡肽酶抑制剂
JP5944922B2 (ja)	2010-12-15	2016-07-05	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ネプリライシン阻害剤
ES2564275T3 (es)	2011-02-17	2016-03-21	Theravance Biopharma R&D Ip, Llc	Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CN103380119B (zh)	2011-02-17	2016-02-17	施万生物制药研发Ip有限责任公司	作为脑啡肽酶抑制剂的经取代的氨基丁酸衍生物
WO2012166390A1 (fr)	2011-05-31	2012-12-06	Theravance, Inc.	Inhibiteurs de néprilysine
CN103748070B (zh)	2011-05-31	2015-06-24	施万生物制药研发Ip有限责任公司	脑啡肽酶抑制剂
ES2653215T3 (es)	2011-05-31	2018-02-06	Theravance Biopharma R&D Ip, Llc	Inhibidores de neprilisina
TWI560172B (en) *	2011-11-02	2016-12-01	Theravance Biopharma R&D Ip Llc	Neprilysin inhibitors
CA2871292A1 (fr)	2012-05-31	2013-12-05	Theravance Biopharma R&D Ip, Llc	Inhibiteurs de neprilysine donneurs d'oxyde nitrique
DK2864292T3 (en)	2012-06-08	2017-07-31	Theravance Biopharma R&D Ip Llc	Neprilysin inhibitors
ES2710932T3 (es)	2012-06-08	2019-04-29	Theravance Biopharma R&D Ip Llc	Inhibidores de neprilisina
BR112015002821B1 (pt)	2012-08-08	2022-10-18	Theravance Biopharma R&D Ip, Llc	Compostos inibidores de neprilisina e composição farmacêutica
WO2014126979A1 (fr)	2013-02-14	2014-08-21	Novartis Ag	Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
CA2900226A1 (fr)	2013-02-14	2014-08-21	Novartis Ag	Derives de l'acide butanoique bisphenyle substitue utiles en tant qu'inhibiteurs de nep presentant une meilleure efficacite in vivo
CA2902456A1 (fr)	2013-03-05	2014-09-12	Theravance Biopharma R&D Ip, Llc	Inhibiteurs de la neprilysine
MX385726B (es) *	2013-11-15	2025-03-18	Hoffmann La Roche	Procesos para la preparación de compuestos de pirimidinilciclopentano.
JP2017507921A (ja)	2014-01-30	2017-03-23	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ネプリライシン阻害剤
JP2017504625A (ja)	2014-01-30	2017-02-09	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ネプリライシン阻害剤としての５−ビフェニル−４−ヘテロアリールカルボニルアミノ−ペンタン酸誘導体
LT3218351T (lt)	2014-11-14	2019-09-25	Zentiva K.S.	Ahu-377 farmaciniu požiūriu priimtinų formų gavimo, atskyrimo ir gryninimo būdas
WO2016097242A1 (fr) *	2014-12-19	2016-06-23	Basf Se	Procédé de préparation de composés carbonyle optiquement actifs
WO2016130650A1 (fr)	2015-02-11	2016-08-18	Theravance Biopharma R&D Ip, Llc	Acide (2s, 4r)-5-(5'-chloro-2'-fluorobiphényl-4-yl)-2-éthoxyoxalkylamino)-2-hydroxyméthyl-2-méthylpentanoïque à titre d'inhibiteur de néprilysine
TW201632493A (zh)	2015-02-13	2016-09-16	諾華公司	新穎方法
RS61325B1 (sr)	2015-02-19	2021-02-26	Theravance Biopharma R&D Ip Llc	(2r,4r)-5-(5'-hloro-2'-fluorobifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina
CN106146351B (zh) *	2015-04-03	2020-09-11	博瑞生物医药（苏州）股份有限公司	制备联芳基取代的4-氨基-丁酸或其衍生物的方法
CN105061263B (zh) *	2015-08-11	2017-03-15	苏州楚凯药业有限公司	一种nep抑制剂中间体的制备方法
CN105152980B (zh) *	2015-09-11	2017-03-29	浙江永宁药业股份有限公司	N‑叔丁氧羰基‑（4s）‑（对苯基苯基甲基）‑4‑氨基‑（2r）‑甲基丁酸的手性制备方法
WO2017051326A1 (fr)	2015-09-23	2017-03-30	Novartis Ag	Nouveaux procédés et intermédiaires utiles dans la synthèse d'inhibiteurs d'endopeptidase neutre (nep)
US10377697B2 (en)	2015-12-10	2019-08-13	Novartis Ag	Process and intermediates
MX2018007129A (es)	2015-12-11	2018-11-09	Zentiva Ks	Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
RU2756223C2 (ru)	2016-03-08	2021-09-28	ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи	Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения
EP3481799A1 (fr)	2016-07-05	2019-05-15	Novartis AG	Nouveau procédé pour des intermédiaires de sacubitril précoces
JP6945619B2 (ja)	2016-08-17	2021-10-06	ノバルティスアーゲー	Ｎｅｐ阻害剤合成のための新規な方法および中間体
WO2018116203A1 (fr)	2016-12-23	2018-06-28	Novartis Ag	Nouveau procédé pour des intermédiaires de sacubitril précoces
EP3421455B1 (fr) *	2017-06-29	2019-03-27	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procédé amélioré pour la préparation de3-amino-piperidins chiraux, des intermédiaires utiles pour la préparation de tofacitinib
CN109912508B (zh) *	2019-04-30	2022-08-12	上海天慈国际药业有限公司	一种右美托咪定及其盐酸盐的制备方法
CN110878039A (zh) *	2019-12-18	2020-03-13	株洲千金药业股份有限公司	一种沙库巴曲缬沙坦钠杂质的制备方法
CN115611857B (zh) *	2022-09-09	2024-05-31	上海伍夫科技有限公司	一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶的制备方法
CN115772088A (zh) *	2022-12-28	2023-03-10	海门瑞一医药科技有限公司	一种叔丁氧基（双二甲胺基）甲烷的制备方法
CN117510376A (zh) *	2023-10-17	2024-02-06	四川新迪生物制药有限公司	一种手性联芳基取代的4-氨基-丁酸及其衍生物的制备方法
WO2025164594A1 (fr) *	2024-01-29	2025-08-07	高砂香料工業株式会社	Complexe de ruthénium-diphosphine-carboxylate et son procédé de production
CN118239990B (zh) *	2024-05-28	2025-03-14	北京元延医药科技股份有限公司	不对称氢化催化合成药物的稀有贵金属和手性膦的配合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3164237D1 (en)	1980-12-23	1984-07-19	Air Ind	Thermo-electrical plants
US5250552A (en)	1991-05-09	1993-10-05	Warner-Lambert Company	3-[thiazolidinone, oxazolidinone, imidazolidinone]-indoles as antiinflammatory agents
US5250522A (en)	1992-10-09	1993-10-05	Ciba-Geigy Corporation	Phosphono/biaryl substituted amino acid derivatives
FR2688503B1 (fr)	1992-03-16	1994-05-06	Synthelabo	Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr)	1991-12-30	1993-07-07	Synthelabo	Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5217996A (en) *	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
US5412102A (en)	1994-05-27	1995-05-02	Syntex (U.S.A.) Inc.	Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB0402262D0 (en)	2004-02-02	2004-03-10	Novartis Ag	Process for the manufacture of organic compounds
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1903027A1 (fr) *	2006-09-13	2008-03-26	Novartis AG	Procédé de préparation de l' acide amino-4 butyrique ou de ses derivés et leur utilisation pour la préparation des inhibiteurs NEP
BRPI0806700A8 (pt) *	2007-01-12	2019-01-22	Novartis Ag	processo
EP2532673A3 (fr)	2007-05-10	2014-01-08	R & D Biopharmaceuticals Gmbh	Dérivés de tubulysine
PE20091364A1 (es) *	2008-01-17	2009-10-13	Novartis Ag	Proceso para la preparacion de inhibidores de nep
CN102712585B (zh) *	2010-01-22	2015-06-24	诺华股份有限公司	中性内肽酶抑制剂中间体和其制备方法
WO2012025502A1 (fr) *	2010-08-23	2012-03-01	Novartis Ag	Nouveau procédé de préparation d'intermédiaires utilisés pour produire des inhibiteurs de l'endopeptidase neutre (epn)
BR112013004164A2 (pt) *	2010-08-23	2016-05-10	Novartis Ag	processo para a preparação de intermediários para a produção de inibidores da nep

2009
- 2009-01-15 PE PE2009000047A patent/PE20091364A1/es not_active Application Discontinuation
- 2009-01-15 AR ARP090100121A patent/AR070176A1/es unknown
- 2009-01-16 RU RU2010133903/04A patent/RU2513521C2/ru not_active IP Right Cessation
- 2009-01-16 JP JP2010544498A patent/JP5739667B2/ja active Active
- 2009-01-16 CN CN201310143383.3A patent/CN103483236B/zh active Active
- 2009-01-16 EP EP09702021.8A patent/EP2245009B1/fr active Active
- 2009-01-16 HU HUE09702021A patent/HUE030606T2/en unknown
- 2009-01-16 KR KR1020107018152A patent/KR101587668B1/ko not_active Expired - Fee Related
- 2009-01-16 CL CL2009000089A patent/CL2009000089A1/es unknown
- 2009-01-16 SI SI200931552A patent/SI2245009T1/sl unknown
- 2009-01-16 SG SG2013004098A patent/SG187491A1/en unknown
- 2009-01-16 NZ NZ586657A patent/NZ586657A/en not_active IP Right Cessation
- 2009-01-16 NZ NZ600119A patent/NZ600119A/xx not_active IP Right Cessation
- 2009-01-16 CA CA2711529A patent/CA2711529C/fr not_active Expired - Fee Related
- 2009-01-16 PL PL09702021T patent/PL2245009T3/pl unknown
- 2009-01-16 TW TW098101721A patent/TWI422370B/zh not_active IP Right Cessation
- 2009-01-16 BR BRPI0906764-7A patent/BRPI0906764A2/pt not_active IP Right Cessation
- 2009-01-16 MY MYPI2010003112A patent/MY169425A/en unknown
- 2009-01-16 WO PCT/EP2009/050510 patent/WO2009090251A2/fr not_active Ceased
- 2009-01-16 AU AU2009204759A patent/AU2009204759B2/en not_active Ceased
- 2009-01-16 CN CN2009801061724A patent/CN101952249B/zh active Active
- 2009-01-16 US US12/863,213 patent/US8580974B2/en active Active
- 2009-01-16 MX MX2010007842A patent/MX2010007842A/es active IP Right Grant
- 2009-01-16 PT PT97020218T patent/PT2245009T/pt unknown
- 2009-01-16 ES ES09702021.8T patent/ES2602564T3/es active Active
2010
- 2010-06-28 IL IL206664A patent/IL206664A0/en unknown
- 2010-06-30 TN TN2010000304A patent/TN2010000304A1/fr unknown
- 2010-06-30 MA MA32970A patent/MA31951B1/fr unknown
- 2010-07-16 GT GT201000211A patent/GT201000211A/es unknown
- 2010-08-12 CO CO10099278A patent/CO6290677A2/es active IP Right Grant
- 2010-08-17 EC EC2010010405A patent/ECSP10010405A/es unknown
2013
- 2013-10-31 RU RU2013148670A patent/RU2636936C2/ru not_active IP Right Cessation
- 2013-11-06 JP JP2013230570A patent/JP5800882B2/ja active Active
- 2013-11-11 US US14/076,302 patent/US9061973B2/en active Active
2015
- 2015-05-18 US US14/715,129 patent/US9227934B2/en active Active
- 2015-11-12 US US14/939,513 patent/US9403766B2/en active Active

Also Published As

Publication number	Publication date
EP2245009A2 (fr)	2010-11-03
AU2009204759B2 (en)	2012-06-07
CN103483236B (zh)	2016-09-28
ECSP10010405A (es)	2010-09-30
ES2602564T3 (es)	2017-02-21
CA2711529C (fr)	2016-11-22
IL206664A0 (en)	2010-12-30
GT201000211A (es)	2014-03-14
KR101587668B1 (ko)	2016-01-22
CN103483236A (zh)	2014-01-01
WO2009090251A2 (fr)	2009-07-23
AR070176A1 (es)	2010-03-17
US9061973B2 (en)	2015-06-23
SI2245009T1 (sl)	2016-12-30
BRPI0906764A2 (pt)	2015-08-18
RU2513521C2 (ru)	2014-04-20
US9403766B2 (en)	2016-08-02
US20110046397A1 (en)	2011-02-24
NZ586657A (en)	2012-06-29
PT2245009T (pt)	2016-11-10
EP2245009B1 (fr)	2016-08-10
HUE030606T2 (en)	2017-05-29
PL2245009T3 (pl)	2017-06-30
CN101952249A (zh)	2011-01-19
WO2009090251A3 (fr)	2009-12-23
CA2711529A1 (fr)	2009-07-23
US20140243546A1 (en)	2014-08-28
KR20100119867A (ko)	2010-11-11
MA31951B1 (fr)	2010-12-01
US20160060217A1 (en)	2016-03-03
NZ600119A (en)	2013-07-26
TW200938188A (en)	2009-09-16
CN101952249B (zh)	2013-10-16
RU2636936C2 (ru)	2017-11-29
AU2009204759A1 (en)	2009-07-23
SG187491A1 (en)	2013-02-28
CO6290677A2 (es)	2011-06-20
US8580974B2 (en)	2013-11-12
CL2009000089A1 (es)	2010-01-22
JP5739667B2 (ja)	2015-06-24
MY169425A (en)	2019-04-04
PE20091364A1 (es)	2009-10-13
JP2014070076A (ja)	2014-04-21
RU2010133903A (ru)	2012-02-27
RU2013148670A (ru)	2015-05-10
MX2010007842A (es)	2010-08-09
US20150246881A1 (en)	2015-09-03
TWI422370B (zh)	2014-01-11
US9227934B2 (en)	2016-01-05
JP5800882B2 (ja)	2015-10-28
JP2011510097A (ja)	2011-03-31

Publication	Publication Date	Title
TN2010000304A1 (en)	2011-11-11	New processes
MY146660A (en)	2012-09-14	Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
JO3142B1 (ar)	2017-09-20	طريقة تحضير 5-ثنائي فينيل -4-أمينو-2-ميثيل بينتانويك أسيد
NZ592497A (en)	2013-02-22	Derivatives of 1-amino-2-cyclobutylethylboronic acid
MX2009002121A (es)	2009-05-20	Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
MX2013000295A (es)	2013-05-28	Procedimiento de preparacion de un inhibidor especifico de la trombina.
MX340214B (es)	2016-06-30	Procedimiento para la preparación de compuestos útiles como inhibidores del transportador de glucosa dependiente de sodio 2.
RU2013112856A (ru)	2014-09-27	Новый способ получения промежуточных соединений, используемых при получении ингибиторов nep
MX2010010502A (es)	2010-10-26	Inhibidores de desacetilasas b a base de hidroxamato.
RU2013112946A (ru)	2014-09-27	Способ получения промежуточных соединений для получения ингибиторов nep
MX2011007978A (es)	2011-08-15	Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2009013869A (es)	2010-03-17	Proceso para hacer 2-amino-tiazolonas sustituidas.
MX2010013758A (es)	2011-03-02	Procedimiento para elaborar 2-amino-tiazolonas sustituidas.
MX2012002818A (es)	2012-04-19	Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MY144746A (en)	2011-10-31	Process for the preparation of agomelatine
UA102816C2 (ru)	2013-08-27	Способ синтеза кристаллической формы v агомелатина
MX2010003184A (es)	2010-10-05	Nuevo procedimiento de sinstesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2009005880A (es)	2009-06-12	Ciclohexenil-butenonas y composiciones de fragancia que las comprenden.
DE602007010725D1 (de)	2011-01-05	Verfahren und zwischenprodukt zur herstellung von donezepil
DE602007007773D1 (de)	2010-08-26	Verfahren zur synthese von ibandronat-natrium
MX2009001508A (es)	2009-02-18	Un proceso novedoso para preparar ester de acido 3-amino-5-fluoro-4-dialcoxipentanoico.
TH123096A (th)	2013-04-30	กระบวนการใหม่
WO2009141833A3 (fr)	2010-11-25	Procédé amélioré pour synthétiser de l'atomoxétine extrêmement pure
WO2012085935A3 (fr)	2013-09-26	Composés utilisés comme inhibiteurs de la rénine
TN2010000362A1 (en)	2011-12-29	Oxim derivatives as hsp90 inhibitors